drugset / Trial / NCT03913117
Study of Treatment for HPV16+ ASC-US or LSIL
Phase 1
Recruiting
30 enrolled
University of Alabama at Birmingham
Johns Hopkins University · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine
Timeline
- Start
- 2023-07-10
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TA-CIN | Vaccine | — | Intramuscular |
| Subject | pNGVL4aCRTE6E7L2 | Vaccine | 0.3 mg | Intramuscular |
| Subject | pNGVL4aCRTE6E7L2 | Vaccine | 1 mg | Intramuscular |
| Subject | pNGVL4aCRTE6E7L2 | Vaccine | 3 mg | Intramuscular |